quinazolines has been researched along with puromycin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, Y; Kakuta, H; Koiso, Y; Nagasawa, K | 1 |
| Hashimoto, Y; Kakuta, H; Nagasawa, K; Tanatani, A | 1 |
| Ang, GCK; Chang, KT; Guccione, E; Hebrard, M; Lee, VK; Leung, JY; Lim, HJ; Pal, A; Pignata, L; Rao, VK; Taneja, R | 1 |
3 other study(ies) available for quinazolines and puromycin
| Article | Year |
|---|---|
Fluorescent bioprobes for visualization of puromycin-sensitive aminopeptidase in living cells.
Topics: Aminopeptidases; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Kinetics; Microscopy, Fluorescence; Puromycin; Quinazolines; Tumor Cells, Cultured | 2003 |
Specific nonpeptide inhibitors of puromycin-sensitive aminopeptidase with a 2,4(1H,3H)-quinazolinedione skeleton.
Topics: Aminopeptidases; Animals; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Electrochemistry; Humans; Kinetics; Magnetic Resonance Spectroscopy; Mice; Neoplasm Invasiveness; Protease Inhibitors; Puromycin; Quinazolines; Structure-Activity Relationship | 2003 |
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Nude; Puromycin; Pyrazines; Pyridines; Quinazolines; Rhabdomyosarcoma, Embryonal; RNA Interference; Wnt Signaling Pathway | 2020 |